• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

    25.50 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 133
    Open 25.50
    Bid (Size) 24.89 (100)
    Ask (Size) 26.70 (100)
    Prev. Close 25.50
    Today's Range 25.50 - 25.50
    52wk Range 20.32 - 40.22
    Shares Outstanding 44,188,534
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -17.5%
    -17.5%
    1 Month
    -18.3%
    -18.3%
    3 Month
    -21.3%
    -21.3%
    6 Month
    -19.7%
    -19.7%
    1 Year
    +3.1%
    +3.1%

    More News

    Read More
    News headline image
    Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
    From Biogen Inc.
    Via GlobeNewswire
    Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion ↗
    Via Chartmill
    News headline image
    Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts ↗
    Via MarketBeat
    News headline image
    Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Present at Upcoming Investor Conferences in June
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics
    Via Business Wire
    News headline image
    Stoke Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
    Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
    The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
    What is the current price of Stoke Therapeutics, Inc. - Common Stock?
    The current price of Stoke Therapeutics, Inc. - Common Stock is 25.50
    When was Stoke Therapeutics, Inc. - Common Stock last traded?
    The last trade of Stoke Therapeutics, Inc. - Common Stock was at 09/28/26 04:00 PM ET
    What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
    The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.13B
    How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
    Stoke Therapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.